Sustained release composns preparation of Fudosteine and clarithromycin
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- GUANGZHOU YOUYI PHARMA SCI & TECH DEV
- Publication Date
- 2006-09-20
- Estimated Expiration
- Not applicable · inactive patent
Abstract
Description
Technical field
[0001] The present invention relates to a medicine. More specifically, the present invention relates to a sustained-release combined preparation of Fudostan and clarithromycin. Background technique
[0002] The chemical name of Fudosteine is (-)-(R)-2-amino-3-(3-hydroxypropylmercapto)propionic acid, which was developed by Japan's SS Pharmaceutical Company and licensed to Japan's Yoshitomi Pharmaceutical the company. The drug was officially launched in 2002 under the trade names of Cleanal (SS Company) and Spelear (Gifford Company). Fudosteine is a new cysteine derivative with a stronger expectorant effect. At present, there are imported preparations of such drugs as ethylcysteine and carbonylmethylcysteine on the market in my country. The curative effect of these drugs is not very satisfactory, especially their toxic side effects are very strong, and their chemical properties are unstable. The expectorant effect of Fudosteine is 3 times that of carbony...